ARCHIVE

read

Allon Therapeutics Remains On-Track to Capitalize on an Unmet Multi-Billion Dollar Market for Alzheimer’s Disease and other Brain Illnesses By Marc Davis, Managing Editor November, 2007 Corporate Overview Allon Therapeutics Inc. (TSX: NPC) is a Vancouver-based biotech pioneer in the development of proprietary drugs that combat some of society’s most pervasive neurodegenerative conditions, including Alzheimer's disease. Most significantly, the company’s two leading multi-application in-development drugs (known as compounds) exhibit “blockbuster drug” potential – representing a prospective multi-billion dollar combined marketplace.